Monday's small-cap news flow split cleanly between energy operators managing turnarounds and acquisitions, and growth companies confronting client caution head-on. Kistos Holdings held its full-year production guidance steady even as a planned Jotun FPSO turnaround dented third-quarter output, while Mind Gym became the session's cautionary tale, slashing revenue guidance as corporate clients pulled back HR spending. Elsewhere, Invinity Energy Systems moved to shore up its balance sheet with a £20m fundraise, and ProBiotix Health delivered the kind of profitable growth story investors like to see.
Kistos holds full-year guidance despite Jotun turnaround hit
Kistos Holdings (AIM:KIST) reported third-quarter pro forma production of roughly 18,500 boepd, down from 20,800 boepd in the first half, after a planned turnaround at the Jotun FPSO in Norway temporarily curbed output. Shares in the North Sea, Eastern Mediterranean and now Middle Eastern-focused producer fell 4.64% to 298.0p, yet the company maintained full-year guidance of 19,000-21,000 boepd, with year-to-date production to 30 September running at approximately 20,000 boepd.
Nine-month pro forma EBITDA reached roughly $280m, including roughly $75m from Oman, though the third quarter came in below the second as an inventory build and the summer turnaround weighed on the numbers. Cash and near-cash fell to $165m at 30 September from $259m at the end of June, with strong cash generation offset by the completion payment for the Oman Blocks 3 & 4 acquisition, heavy capital expenditure and roughly $32m of debt repayment; adjusted net debt widened to $101m from $23m over the same period.
The Blocks 3 & 4 acquisition from Mitsui E&P Middle East completed on 14 September and will consolidate into group results from 1 October, with production from the newly acquired assets close to plan on new oil from the Safi and AGW areas, while the related Block 9 acquisition is now expected to complete in the fourth quarter after the operator added a fifth drilling rig.
"The structure of the Omani offtake agreement means that in the event that oil prices fall, we will continue to benefit from higher prices for at least two to three months, further enhancing EBITDA," said Andrew Austin, Executive Chairman.
The widening of net debt alongside a near-$100m cash drawdown underscores how capital-intensive this year's Omani expansion has been, even as operational guidance holds firm. What matters now is execution: with Block 9 completion pushed into the fourth quarter and the Jotun turnaround behind it, Kistos needs the newly consolidated Oman production to deliver the cash generation that justifies the balance sheet stretch, particularly given the offtake structure's built-in buffer against falling oil prices that Austin is leaning on to reassure investors.
Mind Gym cuts full-year guidance as HR clients pull back spending
Mind Gym (AIM:MIND), trading at 5.875p, told investors it now expects full-year revenue of circa £25m, downgrading its outlook after corporate clients slashed HR spending in the first half. The human capital and business improvement group, midway through a transformation from episodic training provider into what it calls a strategic behavioural-change partner, said half-year revenue for the six months to 30 September will come in at £11.5m, down 15% from £13.5m a year earlier, as clients cut back amid uncertainty over AI, supply chain pressures and energy costs.
The adjusted EBITDA loss for the half is expected to widen to £2.6m, against a £1m loss in the same period last year, driven by the lower revenue and a higher proportion of lower-margin face-to-face delivery. Recurring licence revenue was the bright spot, rising 45% year-on-year to an expected £2.1m and reaching roughly 17% of total first-half revenue, continuing the shift toward the subscription-style model management is betting on.
The widening loss against growing recurring revenue tells two different stories at once: the legacy training business is shrinking faster than the new licence model can offset it. Until recurring revenue reaches a scale that can absorb corporate belt-tightening, Mind Gym's transformation narrative remains a bet on timing as much as strategy.
Invinity suspends shares to launch £20m fundraise
Invinity Energy Systems (AIM:IES) announced plans to raise at least £20m in gross proceeds through a subscription, an institutional placing and a separate retail offer, all priced at 10p per new ordinary share. Shares in the vanadium flow battery maker, last at 17.7p and down 1.67%, entered a capital access window at 7.30am, a voluntary AIM trading pause designed to help companies reach a broader investor base during a fundraise, with trading expected to resume once it concludes.
The company said it has already received strong indications of interest from existing shareholders and potential new investors to support the subscription and placing, though full terms will be announced in due course. Completion is subject to shareholder approval at a general meeting, with a circular to be posted once the fundraise has been finalised.
Pricing the raise at 10p, well below the last traded 17.7p, signals a sizeable dilution for existing holders, even as it points to urgency in shoring up the balance sheet. The scale of the ask relative to Invinity's market size suggests this capital is intended to fund growth commitments rather than simply plug a near-term gap, making the eventual terms and take-up the real test of investor confidence once trading resumes.
ProBiotix Health swings to EBITDA profit as sales jump
ProBiotix Health (AQSE:PBX) told investors that sales rose 36% to £2.68m in the nine months to 30 September, up from £1.97m a year earlier, with shares edging up 0.82% to 7.0775p. The life sciences company, which develops probiotics for cardiometabolic health, posted EBITDA of £0.15m for the period against a £0.25m loss a year earlier, while gross profit nearly doubled to £1.64m from £0.87m, lifting gross margin to 61% from 54%.
ProBiotix held a cash balance of £1.2m, which it said provides sufficient liquidity to fund planned activities. Chief executive Steen Andersen pointed to "the continued expansion of our customer base, growing pipeline of active sales opportunities and increasing commercial interest at key industry events, including CPhI in Milan and Vitafoods in Barcelona" as reinforcing confidence in the business, with the group's LPLDL probiotic strain underpinning a run of recent regional supply deals including partnerships with Nutrisan in Belgium and iProbio in Slovakia.
The swing from loss to profit on a 36% revenue jump marks a genuine inflection point rather than a one-off improvement, with margin expansion suggesting the growth is coming through at better quality. The string of regional licensing deals gives ProBiotix a diversified sales base that should make future growth less dependent on any single market.
Diales Group guides full-year profit growth ahead of expectations
Diales Group (AIM:DIAL), trading at 30.5p, issued a trading update guiding full-year profit growth ahead of previous market expectations, a reassuring signal from the construction and engineering disputes consultancy as it heads into year-end.
The upgrade adds to a run of steady operational progress for the group, and comes without any material price reaction disclosed alongside it, suggesting the market had already priced in a degree of resilience from the business heading into the update.
Faron reports final melanoma survival data supporting combination trial
Faron Pharmaceuticals (AIM:FARN) reported final survival data from its melanoma programme supporting progression of a combination trial, with shares falling 5.33% to 34.08p on the update.
The final data set gives Faron a firmer evidential base to take into its next trial phase, though the share price reaction suggests investors are weighing the detail of the results against expectations set ahead of the readout.
Gemfields reports robust pricing in rubies auction
Gemfields Group (AIM:GEM), at 3.25p, reported robust pricing achieved at its latest rubies auction, a result that underlines continuing demand strength for the gemstone miner's output even amid a choppy year for the broader mining sector.
Strong auction pricing feeds directly into Gemfields' cash generation and provides a tangible data point on end-market demand for coloured gemstones, supporting the investment case independent of broader commodity sentiment.
Petro Matad renewables arm signs MoU with Acwa for Mongolia-China power export
Petro Matad (AIM:MATD) shares jumped 12% to 0.98p after its renewables arm signed a memorandum of understanding with Acwa Power covering a prospective Mongolia-to-China power export project.
The deal with a major Middle Eastern utility and developer gives Petro Matad's renewables ambitions credible external backing, marking a strategic diversification for a company whose roots lie in Mongolian oil exploration, and the market's sharp positive reaction reflects the scale of the opportunity such cross-border power export infrastructure could represent.
EnergyPathways secures data deal to cut MESH costs by £20m
EnergyPathways (AIM:EPP) shares fell 10.59% to 5.15p despite the company securing a data deal expected to cut costs on its MESH energy storage project by £20m, as the company looks to bring down the capital intensity of its flagship scheme.
Mulberry reports 18% sales growth in first half
Mulberry Group (AIM:MUL) reported 18% sales growth for the first half, with shares dipping slightly to 229.0p, down 0.866%, as the luxury leather goods maker continues its turnaround under chief executive Andrea Baldo.
RC365 wins additional HK$2m development deal with wealth management client
RC365 Holding (LSE:RCGH) secured an additional HK$2m development deal with an existing wealth management client, though shares fell 8.333% to 5.5p on the update.
Volex guides FY2027 profit towards top of forecasts after record first half
Volex (AIM:VLX) guided FY2027 profit towards the top end of market forecasts following a record first half, though shares fell 6.22% to 597.378p despite the upbeat outlook.
Clean Power Hydrogen narrows cause of testing incident
Clean Power Hydrogen (AIM:CPH2) narrowed down the cause of a previously disclosed testing incident, with shares falling 4.26% to 1.125p as the electrolyser developer works through the technical review.
ITM Power posts record revenue as EBITDA losses narrow sharply
ITM Power (AIM:ITM) posted record revenue with EBITDA losses narrowing sharply, though shares slipped 1.58% to 90.5p as the hydrogen electrolyser maker continues its path toward profitability.
Sunda Energy wins 12-month extension on Timor-Leste gas licence
Sunda Energy (AIM:SNDA) secured a 12-month extension on its Timor-Leste gas licence, giving the company more time to advance the asset, with shares down 3.333% to 1.45p.
Hemogenyx tests off-the-shelf route for CAR-T therapy
Hemogenyx Pharmaceuticals (LSE:HEMO) advanced testing of an off-the-shelf route for its CAR-T therapy programme, with shares rising 3.25% to 679.38p on the progress.
Gelion gets independent US validation of sulfur battery cathode
Gelion (AIM:GELN), trading at 13.25p, secured independent US validation of its sulfur battery cathode technology, a milestone that lends external credibility to the group's battery chemistry development programme.
Serica trims 2026 production guidance on extended Triton outage
Serica Energy (AIM:SQZ) trimmed its 2026 production guidance after an extended outage at the Triton facility, with shares falling 2.29% to 273.6p on the update.
Beeks extends exchange contracts and plots AI network push
Beeks Financial Cloud Group (AIM:BKS) extended key exchange contracts and outlined plans for an AI-focused network push, with shares down 2.17% to 180.0p despite the strategic update.
Intercede secures £1.04m US Federal purchase order
Intercede Group (AIM:IGP) secured a £1.04m purchase order from a US Federal customer, with shares at 131.5p as the cybersecurity software group continues to build out its government client base.
GenIP soft-launches Invention Evaluator platform ahead of December rollout
GenIP (AIM:GNIP) soft-launched its Invention Evaluator platform ahead of a full December rollout, with shares at 2.65p as the company builds toward commercial launch of its IP assessment tool.
Mindflair portfolio companies win fresh industry recognition
Mindflair (AIM:MFAI) saw several of its portfolio companies win fresh industry recognition, though shares slumped 15.38% to 0.275p despite the positive portfolio news.
Nuformix reports fresh evidence of TGF-β pathway engagement for NXP002
Nuformix (LSE:NFX) reported fresh evidence of TGF-β pathway engagement for its NXP002 programme, with shares rising 4.545% to 0.115p on the data.
TheraCryf clears final toxicology hurdle for Ox-1 trial bid
TheraCryf (AIM:TCF) cleared a final toxicology hurdle in its bid to advance the Ox-1 programme into trials, with shares at 0.175p as the clinical-stage group moves closer to human studies.
Tekcapital's Innovative Eyewear wins TIME Best Inventions award
Tekcapital (AIM:TEK) portfolio company Innovative Eyewear won a TIME Best Inventions award, with Tekcapital shares falling 2.67% to 2.55p despite the recognition for its smart-glasses venture.
Kodal Minerals expands into Ghana lithium exploration
Kodal Minerals (AIM:KOD) expanded its exploration footprint into Ghana lithium assets, with shares falling 6.67% to 0.28p as the company broadens beyond its existing Mali lithium project.
Reveille Resources recruits new lead geologist
Reveille Resources (AQSE:REV) recruited a new lead geologist, strengthening its technical team as the exploration company advances its project work.
80 Mile agrees terms to sell Finnish copper projects to Badlands Resources
80 Mile (AIM:80M) agreed terms to sell its Finnish copper projects to Badlands Resources, with shares down 2.12% to 1.0179p as the company streamlines its portfolio.
US Solar Fund extends sale exclusivity again as regulatory timeline lengthens
US Solar Fund (LSE:USFP) extended sale exclusivity with its prospective buyer again as the regulatory approval timeline lengthens, with shares at 28.0p as the long-running disposal process continues.
Savannah clears key environmental hurdle for Boticas bypass road
Savannah Resources (AIM:SAV) cleared a key environmental hurdle for the Boticas bypass road linked to its lithium project, with shares down 1.31% to 5.0333p on the update.
PureTech's LYT-200 data to feature in ESMO oral presentation
PureTech Health (LSE:PRTC) will see LYT-200 data featured in an oral presentation at the ESMO conference, with shares down 1.22% to 113.2p ahead of the presentation.